Importantly, non-hormone-dependent (i.e., triple-negative or HER2-positive) breast cancer treatment also includes immunotherapy, a promising new field in breast cancer therapy (Emens, 2018; Keenan and Tolaney, 2020). Here, ERBB2 is linked to breast cancer.